Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day) compared with placebo in adult subjects with attention deficit/hyperactivity disorder (ADHD). The efficacy response will be measured by the change in the sum of the inattention and hyperactivity/impulsivity subscale scores of the investigator-rated Conners' Adult ADHD Rating Scale (CAARS), from start of treatment to the end of the double-blind phase.
Critère d'inclusion
- Attention-Deficit/Hyperactivity Disorder (ADHD)